Mirati's SAPPHIRE trial in NSCLC terminated, results posted on ClinicalTrials.govSep 30Trial updateBristol Myers Squibbnivolumab
BeyondSpring gets FDA Fast Track for plinabulin, sells China unit stake to fund trialSep 29Regulatory milestoneBeyondSpring Pharmaceuticals Inc.
BeyondSpring files $11.9 million at-the-market offering with CitizensSep 29FinancingBeyondSpring Pharmaceuticals Inc.
AbbVie registers Phase 3 trial of telisotuzumab adizutecan in NSCLCSep 16Trial updateAbbVietelisotuzumab adizutecan
Pyxis Oncology reports updated Phase 1 data for MICVO in head and neck cancerSep 9Clinical readoutPyxis Oncology, Inc
BeiGene posts results for zanidatamab combo trial in HER2-positive breast, gastric cancersSep 2Trial updateBeiGenetislelizumab
BeyondSpring updates Plinabulin data, names new CEO, reports Q2 2026 resultsAug 14Quarterly updateBeyondSpring Pharmaceuticals Inc.
Candel targets Q4 2026 BLA for prostate cancer therapy, opens NSCLC phase 3 trialAug 13Quarterly updateCandel Therapeutics, Inc.
Vir reports Week 96 SOLSTICE data, ECLIPSE program fully enrolled, VIR-5500 expansion underwayAug 5Quarterly updateVir Biotechnology, Inc.VIR-5500
ORIC Pharmaceuticals starts Phase 3 Himalayas-1 trial, adds Bayer supply dealAug 3Quarterly updateORIC Pharmaceuticals
NuCana's NuTide:303 trial for NUC-3373 combos terminated; results posted with 19 enrolledJul 23Trial updatefosifloxuridine nafalbenamideNuCana plc
ORIC Pharmaceuticals registers Phase 3 Himalayas-1 trial for rinzimetostat in mCRPCJul 23Trial updateBayerdarolutamide
AstraZeneca posts PASSAGE Phase 4 tezepelumab results; registers new prostate, lung, and NF2 trialsJul 17Weekly roundup, 6 itemsAstraZenecaosimertinib
Telix and FDA align on ProstACT Global Phase 3 protocol, IND amendment pendingJul 2Clinical readoutTelix Pharmaceuticals Ltd
GSK's DREAMM 12 posts results with 36 enrolled; COSTAR Lung stays active, not recruitingJul 1Weekly roundup, 2 itemsbelantamabbelantamab mafodotin
Sign inSign in